GIOTRIF® :
The 1st choice in 1st-line
Superior efficacy vs gefitinib and vs chemotherapy
demonstrated in 3 large trials in 1st-line EGFR M+ NSCLC1-4*
demonstrated in 3 large trials in 1st-line EGFR M+ NSCLC1-4*
South Korean Dataset: Frontline Giotrif in Uncommon EGFR Mutations
Document ID: PC-MY-102483
14/06/2022
Author: Boehringer Ingelheim
123,000
Views
100k 340
RELATED CONTENT
PC-MY-102483
Production date: June 2022
Production date: June 2022
